Pharmaceutical Technology

JUNE 29, 2022

This year has already been eventful when it comes to the development of therapies for rare diseases. Most, if not all, of these therapies used the FDA’s Orphan Drug Designation to aid their development plans. Additionally, pricing and access for rare disease therapies continue to be scrutinized closely.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

JANUARY 18, 2022

The hope is that they will harness and re-programme natural cellular mechanisms to selectively remove the disease driving proteins from human tissues, working by boosting interactions – gluing – between therapeutically relevant proteins and the machinery used by cells to naturally tag and destroy proteins.

Immunization 52

Immunization 52

pharmaphorum

MAY 10, 2022

As with Aduhelm (aducanumab), lecanemab is being filed via the accelerated approval pathway, with the companies seeking a green light on the strength of the results of a phase 2b trial ahead of the readout of the confirmatory Clarity AD trial, due in the autumn.

FDA 40

FDA 40

pharmaphorum

SEPTEMBER 15, 2020

Pharma’s go-to-market strategies have tended to be more traditional than those seen in non-regulated sectors, but there are some signs this is changing, with an acceleration in the pace of change forced by the COVID-19 pandemic that is allowing the industry to close its gap with faster, more nimble consumer brands. Jeremy Richter, Tag.

Communication 109

Communication Documentation Labelling Vaccines 109

pharmaphorum

OCTOBER 29, 2021

Rival drug Tecentriq (atezolizumab) – had its accelerated approval in first-line TNBC withdrawn by developer Roche in the US after failing a confirmatory trial, but is in late-stage testing as a treatment for early-stage TNBC. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on.

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

JANUARY 21, 2022

Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone. Medical science is accelerating at a tremendous rate, leading to profound changes in the treatment landscape for many diseases over the last decade. “It

Insurance 52

Insurance Vaccines 52

Roots Analysis

JANUARY 28, 2024

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

Health and Personal Care Stores 40

Health and Personal Care Stores Medical Records Hospitals 40

pharmaphorum

JUNE 2, 2022

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. As covered in a previous article , the importance of R&D to develop treatments for rare diseases is high. The price is right.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

The FDA Law Blog

JUNE 27, 2023

This includes both forging the application of the FDAMA 115 “single study plus confirmatory evidence” standard as well as expanding the use of accelerated approval for products in conditions outside of cancer. We are proud as a firm of this honor and would also like to extend congratulations to all of this year’s Law360 Rising Stars!

FDA 81

FDA 81

pharmaphorum

MAY 24, 2021

It is a newer concept for pharma marketers, however, who are now turning to modular solutions in response to the accelerated demand for content over the past year. Robb DeFilippis, managing director, life sciences, for end-to-end global creative production and sourcing partner Tag in the Americas agrees. ” Robb DeFilippis.

Communication 83

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 83

PharmaShots

MARCH 9, 2023

Her notable achievements can be attributed to the fact that she has been acclaimed with the Kenneth Rainin Foundation Synergy Award, Robert Wood Johnson Harold Amos Medical Faculty Development Award, Immunology Faculty Mentor of the Year, and Gastroenterology & Hepatology Teaching Award. LinkedIn Total experience: 16 yrs.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

European Pharmaceutical Review

JULY 11, 2022

The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . Initial development and validation of the prototype mosaic?8 8” nanoparticles. . The mosaic?8

Vaccines 94

Vaccines Immunization 94

pharmaphorum

OCTOBER 4, 2022

Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. The Moonshot was started with three aims: to accelerate scientific discovery in cancer, foster greater collaboration between stakeholders, and to improve the sharing of cancer data.

Documentation 98

Documentation Data Entry HIPAA Insurance 98